Company Overview

Presentation is prepared for Skolkovo Foundation

2012

Key Facts

• Company status

• Founded

• Our mission

• Main focus

• Technology platform

• Investors

• Partners

2

Private Russian biotech company

2010

Developing and marketing innovative biopharmaceutical drugs targeting the most prevalent and dangerous systemic diseases

Oncology

Cell-penetrating peptides (CPP)

Maxwell Biotech Venture Fund

Maxwell Biotech Group

RVC

Skolkovo

StageProduct Screening Lead

optimization Preclinical Phase 1 Phase 2a

MM-D37K

MM-D37K

Novel peptides

Colorectal cancer

Other indications

2012 goals:

• Receiving clinical trial permission for Phase 1/2a on patients with gastrointestinal cancers;

• R&D activities — in silico, in vitro and in vivo screening and optimization

Pipeline

Colorectal cancer

Other indications

Furtherdevelopment

3

MM-D37K Summary

• Product: chimeric peptide based on CPP platform technology for colorectal cancer (CRC) treatment with possible expansion to other cancer treatment indications;

• Mechanism of action: activates apoptosis in cancer cells using cycline-dependent kinase inhibition mechanism;

• Market potential: Global CRC market ~ $7 billion with unmet clinical need to decrease toxicity of current

chemotherapy as well as to prolongate life of patients with metastatic forms of cancer; Russian CRC market- $60 million;

• Competitive advantages: low peptide toxicity together with additive/synergiс effect with traditional chemotherapeutic agents;

• In vitro and in vivo activity demonstrated in different tumor types;

• Development status: preparing regulatory registration package to initiate clinical trials on patients with gastric cancers.

4

Global CRC Market

• Volume ~ $7 bln in 2011;

• Forecast ~ $11.5 bln in 2017 ;

• Drivers: population growth, increase in life expectancy, cancerogenic diet.

Colorectal cancer is a type of cancer characterized by neoplasia in the colon, rectum, or vermiform appendix

Number of new CRC cases diagnosed per

year

CRC is one of the leading causes of all cancer deaths worldwide and accounts for more than 600 000 deaths every year (WHO, 2011).

Market Overview (CRC)

5

488 000520 000

550 000

31%

13%

9%

31%

13% 3%

Current colorectal cancer therapies remain very toxic and do not improve quality of life for patients with metastatic cancer.

Monoclonal antibodies Pt based agents Topoisomerase inhibitors

Antimetabolite compounds

“Gold standard” for current treatment metastatic colorectal cancer treatment- FOLFOX scheme:5-fluorouracil/ Leucovorin/ Oxaliplatin

Global market structure in monetary terms

Bevacizumab

Cetuximab

Panitumumab

Global CRC Market Structure

6

Colorectal cancer is taking third place by prevalence in the structure of all cancers (Russian Oncology Center);

Russian Market (CRC)

7

Incidence

• 50,000 people new cases diagnosed with CRC;

• Incidence increasing over the last 10 years for over 14%;

• Almost 60% of the disease is diagnosed in stage III - IV, when the treatment is difficult and not effective;

Treatment

• 240,000 patients in needed of treatment of colorectal cancer and colon;

• The provision of necessary medicines - 5%;

• Market volume - $60M

p16cyclin-dependent

kinase

p16

MM-D37K

cancer cells

Cell cycle

Apoptosis activation

MM-D37K is a “chimeric” peptide:

1) Transport sequence

2) Cytotoxic sequence

8

cyclin D

• Fast speed of penetration into cells;

• The dynamics of accumulation in normal and tumor cells do not differ on the nature and rate of accumulation;

• The peptide is able to cross the membrane in both directions;

• It is shown that the greatest activity is typical for the p16-Antp vector (MM-D37K);

• High efficacy against wide spectrum of cancer types;

• Additive effect with etoposide, synergistic effect with taxol.

Short-term human tumors:

• The most sensitive lines — colorectal cancer, pancreatic cancer, kidney cancer, breast cancer, gastric cancer;

• Increased level of induced apoptosis in lymphocytes of patients (chronic lymphocytic leukemia) compared with healthy lymphocytes.

MM-D37K (in vitro)

9

MM-D37K (in vivo)

HCT116, control 11,5x13,5 mm

HCT116, MM-D37K 4,5x4,5 mm

• Toxicity/safety studies:

Up to 100 mg/kg – mice, rats and rabbits (both sexes)

MM-D37K administration does not cause pathological changes in the brain, internal and endocrine organs, does not affect water and food consumption.

10

Pharmacokinetic studies:

• Accumulation in vascularised organs – liver, spleen, lung and kidney;

• Fast blood clearance:

- Route of administration — intravenous

- Method of detection- LC-MS (ESI-TOF)

Efficacy studies:

• Activity against gastrointestinal cancers;

• Additive effect with 5-fluorouracil

• Route of administration — intravenous

Typical MS spectra

1) Expansion of MM-D37K indications

2) R&D activities:a) New cell-penetrating sequences searching (in silico)Partner: Moscow State University - Mechanics and Mathematics Faculty

b) New cytotoxic sequences searching (in silico)Partners: - Moscow State University – Biological Faculty (department of biophysics)- Moscow Institute of Physics and Technology

Bladder cancer Liver cancerStomach cancer GlioblastomaPancreatic cancer

Pipeline Development

11

R&D Activities

12

Peptide screening based on:

•Best energy binding with target protein CDK4(6) – Vina and Umbrella sampling methods;

•Conformation changes in target protein CDK4(6).

Black — in vitro results of different p16 sequences (Fåhraeus R et al “Characterization of the cyclin-

dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule”

Oncogene. 1998 Feb 5;16(5):587-96.)

Red — computer modeling results

Possible commercialization results:

•pipeline development — p16 protein sequence optimization;

•pipeline/collaboration development — new sequences that inhibit “hot” targets;

•custom services — new sequences that inhibit “hot” targets for biotech companies and big pharma.

Publications

•“Effect of metabolizable peptide p16INK4a on short-lived human tumor cultures”. Bozhenko VK, Kulinich TM, Ivanov AV, Kudinova EA, Shishkin AM, Kharchenko VP. Vop. Onkol. 2009;55(4):451-4;

•“Cytostatic and cytotoxic properties of chimeric peptides containing cyclin-inhibiting fragments”. Kulinich TM, Kharchenko VP, Filyasova EI, Shishkin AM, Bozhenko VK.Bull Exp Biol Med. 2008 Jan;145(1):37-40.;

•“Cytotoxicity of chimera peptides incorporating sequences of cyclin kinases inhibitors”.Kharchenko VP, Kulinich VG, Lunin VG, Filiasova EI, Shishkin AM, Sergeenko OV, Riazanova EM, Voronina OL, Bozhenko VK.Vopr Onkol. 2007;53(4):448-52;

•2 additional publications are coming soon:

-Preclinical summary of MM-D37K;

-Novel methods of molecular dynamics screening.

13

№ RU2435787* (issued) EA201100464 PCT/EA 2011/000343

Priority date 29.09.2010 06.04.2011 06.04.2011

Title

«Chimeric peptide and it’s pharmaceutical composition

for cancer disease treatment»

«Pharmaceutical composition for hyperproliferative disease

treatment»

«Pharmaceutical composition for

hyperproliferative disease treatment»

Inventor Bozhenko V.K. Bozhenko V.K. Bozhenko V.K.

Applicant MetaMax, Ltd. MetaMax, Ltd. MetaMax, Ltd.

* «Top-100 inventions in Russia» in 2011 year (Federal Institute of Industrial Property)

Intellectual property

14

Aggressive patent strategy based on R&D activities

Chief Scientific AdviserVladimir Bozhenko, - Professor, PhD, MD, Honored Medical Doctor of the Russian Federation;- Head of Department of Pathology and Laboratory Diagnostics at the Russian

Scientific Center of Radiology;- Member of Dissertation Council at the Russian Federal Research

Center of Radiology (Rosmedtechnology);- author of more than 160 publications and 7 patents.

Chief Executive OfficerAndrey Boldyrev, - project management experience within Russian National Union of

Business Angels;- experience as an expert on intellectual property in the area of "biotechnology"

in the FGU FIPS (Federal service for intellectual property, patent and trademark);

- academic background with honors in biochemistry and professional experience in bioorganic chemistry in Institute of Bioorganic Chemistry (Russian Academy of Science)

Team

15

Yaroslav Kholodov - Ph.D. in Physics and Mathematical Sciences;

- Research Officer, Department of computational mathematics at the Moscow Institute of Physics and Technology;

- Research interests: computer studies and modeling of high-performance computing systems for computer simulation of physical, chemical and biological processes.

Igor Rodionov - Ph.D. in Bioorganic chemistry;

- Deputy Head of the Laboratory of Peptide Chemistry- Branch of Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry (Russian Academy of Science);

- Senior Lecturer, Associate Professor of Pushchino State University;

- Research interests: peptide synthesis, optimization study of adverse reactions, development of new methods for monitoring). Fine custom chemical synthesis of cyclic peptides, lipopeptides.

Advisers

Company is actively uses Maxwell Biotech competencies including scientific, clinical and development assistance.

16

For more information, please contact:

Andrey Boldyrev, CEO

MetaMax, Ltd.

tel: +7 (495) 411-6992

office 3.29, Alexander House,1 Bolshaya Yakimanka str.Moscow, 119180, Russia

boldyrev@metamax.biz

Thank you for your attention